Rationale for the design of combination therapies that are active in T-cell lymphomas?. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 2, n. 13, 2009. DOI: 10.4081/hmr.v2i13.498. Disponível em: https://journals.pagepress.org/hmr/article/view/498. Acesso em: 4 jul. 2025.